Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology

Inclusion Criteria

• •COHORT 1
• •Histologically confirmed cutaneous or mucosal melanoma (per American joint committee on cancer (AJCC) staging system) that is unresectable or metastatic
• •No prior systemic anticancer therapy for unresectable/metastatic melanoma or clinical/radiological disease progression (RECIST1.1) if previously treated and before new treatment
• •No prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as cutaneous carcinoma or cervix)
• •followed in Saint Louis Hospital
• •Tumor tissue available in Saint Louis Hospital
• •Subjects must have signed and approved written informed consent form
• •No pregnancy
• •Any positive test for hepatitis A virus, hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus
• •Histologically confirmed cutaneous or mucosal melanoma
• •Candidates for sentinel lymph node analysis and surgical recovery (this examination is in practice reserved for melanomas \>1mm thick or ulcerated)
• •No prior adjuvant anticancer therapy
• •followed in Saint Louis Hospital
• •Tumor tissue available in Saint Louis Hospital
• •Subjects must have signed and approved written informed consent form
• •No pregnancy
• •Any positive test for hepatitis A virus, hepatitis B virus or hepatitis C virus indicating acute or chronic infection, and/or detectable virus